Repare Therapeutics Inc.

NasdaqGS:RPTX 株式レポート

時価総額:US$147.3m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Repare Therapeutics 過去の業績

過去 基準チェック /06

Repare Therapeuticsの収益は年間平均-5.9%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間15.5% 69.7%割合で 増加しています。

主要情報

-5.6%

収益成長率

68.3%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率51.7%
株主資本利益率-33.6%
ネット・マージン-99.8%
前回の決算情報30 Jun 2024

最近の業績更新

Recent updates

Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data

Aug 30

Will Repare Therapeutics (NASDAQ:RPTX) Spend Its Cash Wisely?

Jul 12
Will Repare Therapeutics (NASDAQ:RPTX) Spend Its Cash Wisely?

Repare Therapeutics Inc.'s (NASDAQ:RPTX) 34% Dip In Price Shows Sentiment Is Matching Revenues

May 01
Repare Therapeutics Inc.'s (NASDAQ:RPTX) 34% Dip In Price Shows Sentiment Is Matching Revenues

Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 30% Plummet

Mar 12
Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 30% Plummet

We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully

Feb 15
We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully

Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Fly 30% But Investors Aren't Buying For Growth

Dec 20
Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Fly 30% But Investors Aren't Buying For Growth

Here's Why We're Not At All Concerned With Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation

Oct 24
Here's Why We're Not At All Concerned With Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation

New Forecasts: Here's What Analysts Think The Future Holds For Repare Therapeutics Inc. (NASDAQ:RPTX)

Aug 14
New Forecasts: Here's What Analysts Think The Future Holds For Repare Therapeutics Inc. (NASDAQ:RPTX)

Analysts Are Betting On Repare Therapeutics Inc. (NASDAQ:RPTX) With A Big Upgrade This Week

May 14
Analysts Are Betting On Repare Therapeutics Inc. (NASDAQ:RPTX) With A Big Upgrade This Week

Analysts Are Upgrading Repare Therapeutics Inc. (NASDAQ:RPTX) After Its Latest Results

May 12
Analysts Are Upgrading Repare Therapeutics Inc. (NASDAQ:RPTX) After Its Latest Results

Repare Therapeutics Inc. (NASDAQ:RPTX) Looks Inexpensive But Perhaps Not Attractive Enough

May 08
Repare Therapeutics Inc. (NASDAQ:RPTX) Looks Inexpensive But Perhaps Not Attractive Enough

Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31%

Mar 03
Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31%

Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth

Oct 27
Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth

Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma Partners

Sep 07

Repare Therapeutics GAAP EPS of -$0.91 misses by $0.06, revenue of $0.67M

Aug 04

Repare Therapeutics: Interesting Gene Editing Company, But Miles To Go

Jun 27

Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth

Jun 24
Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth

Repare Therapeutics (NASDAQ:RPTX) Is In A Good Position To Deliver On Growth Plans

Mar 02
Repare Therapeutics (NASDAQ:RPTX) Is In A Good Position To Deliver On Growth Plans

We're Not Worried About Repare Therapeutics' (NASDAQ:RPTX) Cash Burn

Oct 14
We're Not Worried About Repare Therapeutics' (NASDAQ:RPTX) Cash Burn

We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth

Apr 16
We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth

Have Repare Therapeutics Inc. (NASDAQ:RPTX) Insiders Been Selling Their Stock?

Mar 12
Have Repare Therapeutics Inc. (NASDAQ:RPTX) Insiders Been Selling Their Stock?

Are Institutions Heavily Invested In Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares?

Feb 08
Are Institutions Heavily Invested In Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares?

Repare Therapeutics: CRISPR-Enabled Technology Might Unlock New Therapies

Dec 28

Trade Alert: The Executive VP & Head of Business & Corporate Development Of Repare Therapeutics Inc. (NASDAQ:RPTX), Kim Seth, Has Sold Some Shares Recently

Dec 21
Trade Alert: The Executive VP & Head of Business & Corporate Development Of Repare Therapeutics Inc. (NASDAQ:RPTX), Kim Seth, Has Sold Some Shares Recently

収支内訳

Repare Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGS:RPTX 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Jun 2469-69360
31 Mar 2498-46360
31 Dec 2351-94360
30 Sep 2356-97350
30 Jun 23167-3350
31 Mar 23137-29350
31 Dec 22132-29350
30 Sep 22121-26340
30 Jun 228-132330
31 Mar 228-120320
31 Dec 218-107280
30 Sep 211-94250
30 Jun 211-77220
31 Mar 210-62190
31 Dec 200-53160
30 Sep 200-4612-14
30 Jun 200-4010-9
31 Mar 200-357-4
31 Dec 190-2760
31 Dec 180-14310

質の高い収益: RPTXは現在利益が出ていません。

利益率の向上: RPTXは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: RPTXは利益が出ておらず、過去 5 年間で損失は年間5.9%の割合で増加しています。

成長の加速: RPTXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: RPTXは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。


株主資本利益率

高いROE: RPTXは現在利益が出ていないため、自己資本利益率 ( -19.7% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘